ライフサイエンスコーパス: , with no

1 ocal adhesion phosphorylation and IL-13-enhanced contraction, with no additional effect from chymase.

2 ctivated is sufficient to accurately represent odor identity, with no additional information about identity provided by s

3 ects of antibiotics were phenocopied in Stat1-deficient mice, with no additional suppression by antibiotics in these mice

4 of the hybrid perovskite semiconductor (MA)PbI3 (MA = CH3NH3(+)) with no apparent structural transition.

5 he population prevalence for genetic short root anomaly (SRA) with no apparent defects in crown is close to 1.3%.

6 ional therapy is limited to normobaric and hyperbaric oxygen, with no available antidotal therapy.

7 OV offers substantial protection against Ebola virus disease, with no cases among vaccinated individuals from day 10 afte

8 naptogyrin-1) and postsynaptic signaling (e.g., GluA1, PRRT2) with no changes in synaptic GABAergic proteins.

9 catabolism, there is near complete loss of TCA intermediates, with no compensation from glucose-derived anaplerosis.

10 rapy or saline was technically successful in all eight swine, with no complications.

11 d in strong genetic division of populations into two sectors, with no detectable migration between sites.

12 inued to provide superior overall survival versus ipilimumab, with no difference between pembrolizumab dosing schedules.

13 normal interpretation and biopsy rates and lower specificity, with no difference in cancer detection rate.

14 se from baseline in PTH and decline in FGF23 by study week 4, with no differences in creatinine, phosphate, or TRP.

15 and CNF, 90% and 95% of the patients reported symptom relief, with no differences in GERD symptoms or dysphagia.

16 difference less than 1 point on a scale of 1 to 7) at 1 year, with no differences on most measures of quality of life.

17 creening and might produce negative results in as few as 3 h, with no downstream workup.

18 n only about 50%-60% of primary biliary cholangitis patients, with no effective therapy in PSC.

19 VD and CKD risk groups had multiplicative predictive effects, with no evidence of an interaction (p = 0.329 and p = 0.291

20 e, bioengineered artificial ducts can replace the native CBD, with no evidence of cholestasis or occlusion of the lumen.

21 is, compared with patients who do not receive anticoagulants, with no excess of major and minor bleedings and less incide

22 All consenting patients were included, with no exclusion criteria.

23 central nervous system will have a monophasic disease course, with no further clinical or radiological symptoms.

24 RGD-containing peptide abrogated IL-13-enhanced contraction, with no further effect from chymase.

25 ntaining the cold precursors THP-PSMA and sodium bicarbonate, with no further manipulation.

26 tiple comorbidities, and 17.7% of otherwise healthy patients) with no gradient across glycemia levels (20.6% of those wit

27 o increase in vascular occlusive events with tranexamic acid, with no heterogeneity by site of bleeding (p=0.5956).

28 eline (a Mini-Mental State Examination score of 26 or higher) with no history of neurological or psychiatric disorders, a

29 The PVSCs show high efficiency of 17.10% and 14.19%, with no hysteresis on rigid and flexible substrates, respe

30 onophosphoryl lipid A (MPL), blockade Ab titers peaked early, with no increase in titer following a second vaccine dose.

31 achieved SVR, a response rate of 86% (95% CI, 83.0% to 88.7%), with no major safety signals.

32 This bias-selectable dual-band photodetector is compact, with no moving parts, and will open new opportunities for m

33 -significant and in opposing directions for DHCR7 and CYP2R1, with no overall association observed for the synthesis scor

34 n of thymocytes through the maturation stages was unaffected, with no overt signs of developmental blocks.

35 ERX-11 is orally bioavailable, with no overt signs of toxicity and potent activity in both

36 The 30-day mortality rate was 15.3% with no procedure-related deaths.

37 ioenriched bicyclo[3.1.0]hexenes at all levels of conversion, with no racemization or symmetrization taking place during

38 that regulate this pathway were detected in 71% of the women, with no relationship to pregnancy outcome.

39 st trimester (or first trimester and periconceptional period), with no reports of birth defects among fetuses or infants

40 stent within individuals and appear stable in the population, with no reproductive advantage.

41 cimol produced a significant synergistic antipruritic effect, with no sedation.

42 re serotyped (88%) and 35 distinct serotypes were identified, with no serotype predominance.

43 lacebo were significant (p<0.0001 for both groups vs placebo), with no significant difference between the two seladelpar

44 ith novel oral anticoagulants were seen in subgroup analyses, with no significant difference according to the indication

45 d-vein pigmentation length for group 1 and 7.09% for group 2, with no significant difference between the groups (P = .09)

46 children with 2 FLG LOF alleles or TSLPrs1898671 homozygotes, with no significant difference observed between wildtype an

47 onths with C20, 5.1 months with C25, and 5.3 months with D75, with no significant differences between treatment arms.

48 milar clinical outcomes when used as carriers for the B-KPro, with no significant differences in device retention, visual

49 after cataract surgery in patients with diabetic retinopathy, with no unanticipated safety events.

50 tis ranged from 2.51% (95% CI 1.13-3.60) to 3.85% (2.37-5.33), with no unusual variation from the adjusted national incid